Entities / Company
Emergent BioSolutions.
multinational biopharmaceutical company headquartered in Gaithersburg, Maryland, USA
- Reports this week
- 0
- Active events
- 0
- Connections
- 57
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Emergent BioSolutions and Precigen are two healthcare companies that are currently competing for investment.Some support1 report
-
MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.Some support2 reports
-
Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.Some support1 report
-
Emergent BioSolutions is being investigated regarding potential securities law violations.Some support1 report
-
Benzinga reported on stock changes for Emergent BioSolutions, and Benchmark reissued a buy rating on the stock.Some support1 report
-
Renaissance Technologies lifted its stake in Emergent BioSolutions on August 7, 2026.Some support1 report
-
CDC reported US overdose death trends and expanding naloxone access, while Emergent BioSolutions acquired rights to KLOXXADO in Canada.Speculative1 report1 development inside
-
Emergent BioSolutions is facing increased competition and pricing pressure in the naloxone market while undergoing restructuring and accelerating government deliveries.Some support1 report
Gone quiet
No new reports in 90+ days-
Emergent BioSolutions and Silo Pharma, Inc. are undergoing a direct comparison of their financial performance metrics.Some support1 report
-
Emergent BioSolutions used LinkedIn and Spotify for public health updates and participated in a Wells Fargo conference.Some support2 reports
-
OTC naloxone is becoming available in the House of Representatives of Thailand to help reduce overdose deaths.Some support1 report
-
FTSE Russell determined its index membership criteria based on market capitalization.Speculative1 report
-
Emergent BioSolutions secured seven biodefense contract modifications from the U.S. Government.Some support3 reports2 developments inside
-
Emergent BioSolutions supports the U.S. smallpox preparedness strategy.Speculative1 report
-
Mental Health America released a report analyzing national overdose data, coinciding with an activation hosted by Ready to Rescue near Chicago.Some support1 report
-
Emergent BioSolutions received a contract modification from BARDA to supply a vaccine, which had previously been approved by the FDA.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Emergent BioSolutions this week
News at the entities that move Emergent BioSolutions most-
MarketBeat OperationalMarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Moves Emergent BioSolutions
-
Department of Health & Human Services TransactionalHHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.Moves Emergent BioSolutions
-
Renaissance Technologies TransactionalRenaissance Technologies, Sumitomo Mitsui, and Amundi made transactions in Albemarle Corporation stock on October 22, 2026.Moves Emergent BioSolutions
-
Benchmark TransactionalBenchmark lifted its price objective and gave a buy rating for Amazon.com.Moves Emergent BioSolutions
-
company TransactionalJames Currier serves as CEO of the company, which reports to the SEC.Moves Emergent BioSolutions
-
LinkedIn Mentioned togetherBit Digital stakes Ethereum to generate protocol-native yield and uses LinkedIn for investor information.Moves Emergent BioSolutions
Connections
The 11 strongest of 57, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
MarketBeat Operational
Emergent BioSolutions utilizes MarketBeat's platform to access analyst recommendations.
-
Alnylam Pharmaceuticals Operational
Both companies are actively competing for investment within the healthcare sector.
-
Department of Health & Human Services Transactional
Emergent BioSolutions receives contracts from the Department of Health & Human Services.
-
Renaissance Technologies Transactional
Renaissance Technologies lifted its stake in Emergent BioSolutions.
-
Benzinga Mentioned together
Benzinga provides financial reporting and coverage regarding Emergent BioSolutions' stock performance.
-
Nasdaq Shared context
Emergent BioSolutions is a publicly listed company operating within the financial market context.
-
Seattle Shared context
Emergent BioSolutions operates within the geographical and regulatory context of Seattle, evidenced by a major corporate spin-off.
-
Gaithersburg Shared context
Emergent BioSolutions is located in Gaithersburg, where it conducts its operations.
Show all 11 connections
-
company Transactional
The relationship is currently under investigation regarding potential securities law violations.
-
LinkedIn Mentioned together
Emergent BioSolutions utilizes LinkedIn as a platform for public health communication and mission updates.
-
Benchmark Transactional
Benchmark issued a buy rating on the stock of Emergent BioSolutions.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Emergent BioSolutions and Precigen are two healthcare companies that are currently competing for investment.
- MarketBeat provided analyst ratings and targets for small-cap healthcare companies Emergent BioSolutions and Entrada Therapeutics.
- Alnylam Pharmaceuticals (listed on Nasdaq) and Emergent BioSolutions (listed on NYSE) are two healthcare companies competing for investment.
August 2026
4 events- Emergent BioSolutions is being investigated regarding potential securities law violations.
- Benzinga reported on stock changes for Emergent BioSolutions, and Benchmark reissued a buy rating on the stock.
- Renaissance Technologies lifted its stake in Emergent BioSolutions on August 7, 2026.
- Emergent BioSolutions is facing increased competition and pricing pressure in the naloxone market while undergoing restructuring and accelerating government deliveries.
Show 1 earlier month
June 2026
9 events- CDC reported US overdose death trends and expanding naloxone access, while Emergent BioSolutions acquired rights to KLOXXADO in Canada.
- Emergent BioSolutions and Silo Pharma, Inc. are undergoing a direct comparison of their financial performance metrics.
- Emergent BioSolutions used LinkedIn and Spotify for public health updates and participated in a Wells Fargo conference.
- OTC naloxone is becoming available in the House of Representatives of Thailand to help reduce overdose deaths.
- FTSE Russell determined its index membership criteria based on market capitalization.
- Emergent BioSolutions secured seven biodefense contract modifications from the U.S. Government.
- Emergent BioSolutions supports the U.S. smallpox preparedness strategy.
- Mental Health America released a report analyzing national overdose data, coinciding with an activation hosted by Ready to Rescue near Chicago.
- Emergent BioSolutions received a contract modification from BARDA to supply a vaccine, which had previously been approved by the FDA.